<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013479</url>
  </required_header>
  <id_info>
    <org_study_id>DK-CATALYST</org_study_id>
    <nct_id>NCT02013479</nct_id>
  </id_info>
  <brief_title>Selenium Supplementation in Autoimmune Thyroiditis</brief_title>
  <acronym>CATALYST</acronym>
  <official_title>The Chronic Autoimmune Thyroiditis Quality Of Life Selenium Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steen Bonnema</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of South West Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharma Nord</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our aim is to investigate if selenium supplementation versus placebo adjuvant to the standard&#xD;
      treatment with levothyroxine (LT4) in patients with autoimmune thyroiditis will lead to&#xD;
      improved thyroid specific quality of life, and reduced autoimmune activity. The trial will&#xD;
      include 472 participants (2 X 236) from four clinical trial sites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Chronic autoimmune thyroiditis (AIT) is a common autoimmune disease that often&#xD;
      leads to impaired function of the thyroid gland, increases in incidence with age, and has an&#xD;
      8-9 time female preponderance. Quality of life is often impaired and complaints persist in a&#xD;
      considerable number of patients, even after restoration of euthyroidism. The autoimmune&#xD;
      component of the disease has been suggested as an explanation for this. Selenium is a micro&#xD;
      nutritive essential for human health and the thyroid gland has the highest selenium&#xD;
      concentration of all human tissues. Selenoproteins catalyse thyroid hormone metabolism and&#xD;
      anti-oxidative processes in thyrocytes. In addition they are important to immune function. In&#xD;
      Denmark, patients with AIT have lower blood selenium concentration than the background&#xD;
      population. The majority of 13 randomised trials have shown that selenium supplementation&#xD;
      decreases serum thyroid peroxidase antibody levels (TPO-Ab) in patients with AIT, when&#xD;
      compared with placebo. We hypothesise that adjuvant selenium may be beneficial in the&#xD;
      treatment of AIT.&#xD;
&#xD;
      Objectives: To investigate if selenium supplementation versus placebo adjuvant to the&#xD;
      standard treatment with levothyroxine (LT4) in patients with AIT will lead to improved&#xD;
      thyroid specific quality of life, and reduced autoimmune activity.&#xD;
&#xD;
      Design and trial size: The CATALYST trial is an investigator-initiated randomised, blinded,&#xD;
      multicentre clinical trial of selenium supplementation versus placebo in patients with AIT.&#xD;
      The trial will include 472 participants (2 X 236) from four clinical trial sites.&#xD;
&#xD;
      Intervention and duration: The experimental intervention group will receive 200 μg&#xD;
      selenium-enriched yeast as two oral tablets once daily for 12 months. The control group will&#xD;
      receive two placebo tablets, identical in appearance, taste and smell, once daily for 12&#xD;
      months. Six months additional follow-up leads to a trial duration of 18 months. The&#xD;
      experimental supplement will be SelenoPrecise® by Pharma Nord ApS.&#xD;
&#xD;
      Time schedule: July 2012 - February 2014: preparation, approval and trial registration .&#xD;
      March 2014: first participant first visit. March 2016: last participant first visit.&#xD;
      September 2017: last participant last visit. Autumn 2017: analysis of biological samples and&#xD;
      data, preparation of manuscripts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thyroid related quality of life</measure>
    <time_frame>12 months after initation of intervention</time_frame>
    <description>Measured in composite score based on the ThyPRO questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thyroid peroxidase antibody concentration (TPO-Ab)</measure>
    <time_frame>12 months after initation of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levothyroxine (LT4) dosage</measure>
    <time_frame>12 months after initation of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">415</enrollment>
  <condition>Autoimmune Thyroiditis</condition>
  <arm_group>
    <arm_group_label>SelenoPRECISE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SelenoPRECISE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SelenoPRECISE</intervention_name>
    <description>Produced by Pharma Nord ApS, Vejle, Denmark</description>
    <arm_group_label>SelenoPRECISE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Produced by Pharma Nord ApS, Vejle, Denmark</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Serum-TPO-Ab ≥ 100 IU/mL measured within the last 12 months.&#xD;
&#xD;
          3. Receiving LT4 treatment.&#xD;
&#xD;
             - Serum-TSH ≥ 4.0 mU/L measured prior to treatment initiation&#xD;
&#xD;
          4. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous diagnosis of toxic nodular goitre, Graves' hyperthyroidism, post-partum&#xD;
             thyroiditis or thyroid associated orbitopathy (TAO).&#xD;
&#xD;
          2. Previous radioiodine therapy, anti-thyroid treatment or thyroid surgery.&#xD;
&#xD;
          3. Previous diagnosis of non-melanoma skin cancer.&#xD;
&#xD;
          4. Morbidity, rendering the participant unable to process patient reported outcomes or&#xD;
             receive intervention during the trial.&#xD;
&#xD;
          5. Systemic immunomodulatory medication.&#xD;
&#xD;
          6. Other medication known to affect thyroid function.&#xD;
&#xD;
          7. Pregnancy, breastfeeding, or planned pregnancy within 18 months.&#xD;
&#xD;
          8. Allergy towards the components in the selenium or placebo pills.&#xD;
&#xD;
          9. Intake of selenium supplementation ≥ 55 μg/d.&#xD;
&#xD;
         10. Unable to read or understand Danish.&#xD;
&#xD;
         11. Lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steen J Bonnema, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laszlo Hegedüs, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian H Winther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torquil Watt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Cramon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulla Feldt-Rasmussen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Åse K Rasmussen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeppe Gram, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of South West Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nils J Knudsen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology and Gastroenterology, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Hospital of South West Denmark</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Endorcrinology and Metabolism, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Steen Bonnema</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroiditis</mesh_term>
    <mesh_term>Thyroiditis, Autoimmune</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

